SUTRO BIOPHARMA INC
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
STRO$10.61+10.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Comprehensive Loss
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Net loss | $(227,461) | $(106,793) | $(119,204) |
| Other comprehensive income (loss): | |||
| Net unrealized income (loss) on available-for-sale securities | 18 | 639 | (304) |
| Comprehensive loss | $(227,443) | $(106,154) | $(119,508) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.